Advate

RSS

octocog alfa

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Advate. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Advate. For practical information about using Advate, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 15/12/2022

Authorisation details

Product details
Name
Advate
Agency product number
EMEA/H/C/000520
Active substance
octocog alfa
International non-proprietary name (INN) or common name
octocog alfa
Therapeutic area (MeSH)
Hemophilia A
Anatomical therapeutic chemical (ATC) code
B02BD02
Publication details
Marketing-authorisation holder
Takeda Manufacturing Austria AG
Revision
31
Date of issue of marketing authorisation valid throughout the European Union
02/03/2004
Contact address

Industriestrasse 67
1221 Vienna
Austria

Product information

04/07/2022 Advate - EMEA/H/C/000520 - IB/0117

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antihemorrhagics

Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency).

Advate does not contain von Willebrand factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease.

Assessment history

Related content

How useful was this page?

Add your rating
Average
2 ratings
3 ratings